Juergen BluschResearch and Development, Biotechnology, Cell, GMP at Novartis Pharma AG
Dr. Jürgen Hubert Blusch studied biology at the University of Regensburg, Germany. His master and PhD thesis dealt with promoter analysis and signal transduction with experimental work carried out at the Max-Planck-Institute for Biochemistry, Martinsried, Germany. His PhD studies were supported by a Fellowship of the Boehringer Ingelheim Funds.
Focusses of research during his Post-Doc period were mammalian endogenous retroviruses (GSF-Institute for Mammalian Genetics, Neuherberg, Germany), D-type adenoviruses (Gene Center, Ludwig Maximilians-University, Munich, Germany) and finally cross-species virus transfer during xenotransplantation of pig organs (Max-von-Pettenkofer-Institute, Dep. of Virology). His scientific work is documented in related scientific publications in peer-reviewed journals.
His current position is Principal Fellow / Senior Expert Cell Line Analytics within Novartis Pharma Technical Research and Development Quality Assurance. In this role, he is contributing as Subject Matter Expert for viral and TSE safety of biotech products (recombinant proteins produced in mammalian and microbial cells, cell and gene therapy applications). Prior to this, he was serving as Biosafety Officer and was heading the Cell Substrate Analytics group responsible for genetic and adventitious agents testing of production cell banks and bulk harvest for more than 10 years. In the context of adventitious agents testing, he has been working with several contract labs, qualified as supportive and lead auditor. He had been invited to join the WHO Study Group on Cell Substrates for updating WHO TRS878 and previously to the PDA core team for the consultation of the European Guideline for Viral Safety of Investigational Products.